NVAX · XBRL financial data

Novavax financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NVAX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	187	291*	94	415	85	88*	667	239	70	147*	140	57
Revenue from contracts with customers	—	year only	94	415	85	88*	666	239	70	147*	140	57
Cost of revenue	99	155*	59	46	61	37*	14	15	21	22*	31	14
Research and development	106	165*	93	107	87	104*	89	79	98	76*	95	71
Selling, general and administrative	—	year only	—	—	71	78*	48	44	32	34*	29	27
General and administrative	107	155*	87	101	71	—	48	44	—	—	—	—
Operating income (loss)	(126)	(184)*	(145)	161	(134)	(131)*	516	101	(178)	14*	(15)	(55)
Interest income	—	year only	—	9	12	9*	8	7	7	7*	7	7
Interest expense	3	4*	4	4	4	8*	6	6	5	6*	5	6
Other income (expense)	(3)	11*	4	8	16	13*	10	12	9	9*	12	9
Income tax expense (benefit)	(1)	2*	2	2	(1)	7*	1	1	(1)	0*	1	2
Net income (loss)	(131)	(178)*	(148)	162	(121)	(81)*	519	107	(202)	18*	(9)	(53)
Earnings per share, basic USD per share	(1.26)	(1.44)*	(1.05)	1.09	(0.76)	(0.51)*	3.22	0.66	(1.25)	0.11*	(0.06)	(0.32)
Earnings per share, diluted USD per share	(1.26)	—	(1.05)	0.99	(0.76)	—	2.93	0.62	(1.25)	—	(0.06)	(0.32)
Weighted average shares, basic millions of shares	103	124*	140	148	160	160*	161	162	162	163*	163	165
Weighted average shares, diluted millions of shares	103	109*	140	166	160	143*	178	177	162	175*	163	165

Fiscal quarters (NVAX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	651	569	481	680	574	530	263	254	268	241	228	191
Marketable securities	—	0	—	369	336	393	468	359	495	494	562	528
Inventory	70	42	16	9	9	9	10	10	14	12	11	10
Prepaid and other current assets	152	226	199	102	80	78	71	60	46	27	26	23
Total current assets	1,007	1,144	727	1,203	1,104	1,129	868	920	975	978	851	771
Property and equipment, net	301	306	291	289	286	138	134	130	49	45	42	38
Right-of-use asset	—	25	—	—	—	22	134	131	—	20	—	—
Goodwill	124	127	123	123	127	107	112	113	113	113	113	113
Total assets	1,657	1,797	1,354	1,819	1,712	1,560	1,293	1,337	1,180	1,177	1,043	956
Accounts payable	102	133	58	80	58	42	34	51	15	25	16	23
Accrued liabilities	311	395	257	159	219	211	132	87	116	107	103	81
Total current liabilities	1,469	1,635	804	1,158	1,181	1,154	422	389	430	460	342	331
Lease liability, non-current	—	29	—	—	—	23	—	—	—	19	—	—
Total liabilities	2,336	2,514	2,221	2,250	2,239	2,184	1,369	1,299	1,337	1,304	1,188	1,146
Accumulated deficit	(4,643)	(4,821)	(4,969)	(4,806)	(4,927)	(5,008)	(4,490)	(4,383)	(4,586)	(4,568)	(4,578)	(4,631)
Total stockholders' equity	(678)	(717)	(867)	(432)	(526)	(624)	(76)	38	(157)	(128)	(145)	(191)
Total liabilities and equity	1,657	1,797	1,354	1,819	1,712	1,560	1,293	1,337	1,180	1,177	1,043	956
Common shares outstanding (cover page) millions of shares	119	140	140	160	160	161	162	162	162	163	164	165

Fiscal quarters (NVAX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(131)	(178)*	(148)	162	(121)	(81)*	519	107	(202)	18*	(9)	(53)
Stock-based compensation	21*	16*	12	14*	12*	10*	10	9*	9*	8*	8	8*
Depreciation and amortization	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net cash from operating activities	(40)*	(177)*	(84)	314*	(145)*	(173)*	(186)	(127)*	108*	(39)*	(32)	(73)*
Net cash from investing activities	(18)*	(9)*	(7)	(373)*	32*	144*	(73)	111*	(137)*	20*	(28)	35*
Proceeds from issuing common stock	195*	103*	7	256*	0*	0*	0	0*	0*	0*	—	—
Net cash from financing activities	197*	100*	6	258*	(0)*	(3)*	(7)	(1)*	42*	(7)*	38	1*
Net change in cash	148*	(83)*	(88)	200*	(107)*	(43)*	(267)	(9)*	14*	(27)*	(23)	(37)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	165	not reported	(105)*	113.3M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.